Q3 2024 EPS Estimates for Unity Biotechnology, Inc. (NASDAQ:UBX) Boosted by Analyst

Unity Biotechnology, Inc. (NASDAQ:UBX) – Investment analysts at HC Wainwright raised their Q3 2024 earnings estimates for Unity Biotechnology in a research note issued to investors on Wednesday, August 7th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($0.40) for the quarter, up from their prior estimate of ($0.46). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($1.74) per share. HC Wainwright also issued estimates for Unity Biotechnology’s Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.49) EPS, FY2025 earnings at ($1.71) EPS, FY2026 earnings at ($0.59) EPS and FY2027 earnings at $0.20 EPS.

Unity Biotechnology Stock Down 2.7 %

Unity Biotechnology stock opened at $1.44 on Friday. The company’s fifty day simple moving average is $1.45 and its 200-day simple moving average is $1.56. Unity Biotechnology has a 12 month low of $1.22 and a 12 month high of $2.67. The stock has a market cap of $24.18 million, a P/E ratio of -0.57 and a beta of 0.84.

Unity Biotechnology (NASDAQ:UBX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.15.

Institutional Investors Weigh In On Unity Biotechnology

An institutional investor recently bought a new position in Unity Biotechnology stock. Armistice Capital LLC acquired a new stake in shares of Unity Biotechnology, Inc. (NASDAQ:UBX) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 688,000 shares of the company’s stock, valued at approximately $1,328,000. Armistice Capital LLC owned about 4.10% of Unity Biotechnology as of its most recent filing with the Securities & Exchange Commission. 29.49% of the stock is owned by institutional investors and hedge funds.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.